Showing results (81-90 of 195) with videos related to
Sort By:
Pageof 20
Journal of Diabetes and Metabolic Disorders|May 12, 2026
Joint effect of hepatic steatosis index and triglyceride glucose index on cardio-renal outcomes: a real-world studyYun Shen, Lizheng Shi, Vivian Fonseca, et al.Current Medical Research and Opinion|September 27, 2022
Lowering hemoglobin A1c level to less than 6.0% in people with type 2 diabetes may reduce major adverse cardiovascular events: a Bayesian's narrativeHui Shao, Jingchuan Guo, Neda Laiteerapong, et al.Diabetes Care|February 4, 2012
Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)Itamar Raz, Vivian Fonseca, Mark Kipnes, et al.Stem Cells International|January 16, 2018
Mesenchymal Stem Cell Benefits Observed in Bone Marrow Failure and Acquired Aplastic AnemiaVivian Fonseca Gonzaga, Cristiane Valverde Wenceslau, Gustavo Sabino Lisboa, et al.Diabetic Medicine : a Journal of the British Diabetic Association|March 12, 2024
An exploratory analysis of the cost-effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes modelHui Shao, Lizheng Shi, Vivian Fonseca, et al.Current Medical Research and Opinion|September 11, 2010
Healthcare resource utilization, adherence and persistence with antipsychotic therapy among schizophrenia patients with vs. without pre-existing metabolic syndromeLizheng Shi, Yingnan Zhao, Vivian Fonseca, et al.Diabetes Care|July 27, 2005
Relationship between HbA1c level and peripheral arterial diseasePaul Muntner, Rachel P Wildman, Kristi Reynolds, et al.Diabetic Medicine : a Journal of the British Diabetic Association|April 10, 2023
Cost-effectiveness analysis of once-daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes modelHui Shao, Lizheng Shi, Vivian Fonseca, et al.BMC Psychiatry|December 22, 2009
Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health AdministrationLizheng Shi, Haya Ascher-Svanum, Yi-Ju Chiang, et al.Diabetes, Obesity & Metabolism|June 2, 2025
Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesityMan Tang, Lizheng Shi, Dawei Guan, et al.Pageof 20